share_log

Needham Maintains Buy on Veracyte, Lowers Price Target to $30

Benzinga ·  Nov 8, 2023 17:02

Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $35 to $30.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment